Zions Bancorporation N.A. Buys 19,604 Shares of Johnson & Johnson (NYSE:JNJ)

Zions Bancorporation N.A. boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 671.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 22,525 shares of the company’s stock after acquiring an additional 19,604 shares during the quarter. Zions Bancorporation N.A.’s holdings in Johnson & Johnson were worth $3,650,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of JNJ. BCM Advisors LLC boosted its position in Johnson & Johnson by 0.5% during the 3rd quarter. BCM Advisors LLC now owns 39,736 shares of the company’s stock valued at $6,288,000 after buying an additional 188 shares during the period. Plato Investment Management Ltd raised its stake in shares of Johnson & Johnson by 0.4% during the third quarter. Plato Investment Management Ltd now owns 60,397 shares of the company’s stock valued at $9,778,000 after acquiring an additional 214 shares during the last quarter. D Orazio & Associates Inc. boosted its holdings in shares of Johnson & Johnson by 27.5% during the third quarter. D Orazio & Associates Inc. now owns 7,303 shares of the company’s stock worth $1,184,000 after purchasing an additional 1,573 shares during the period. Schrum Private Wealth Management LLC grew its stake in shares of Johnson & Johnson by 50.7% in the third quarter. Schrum Private Wealth Management LLC now owns 10,474 shares of the company’s stock worth $1,698,000 after purchasing an additional 3,526 shares during the last quarter. Finally, Parthenon LLC increased its holdings in Johnson & Johnson by 0.4% during the 3rd quarter. Parthenon LLC now owns 126,275 shares of the company’s stock valued at $20,464,000 after purchasing an additional 442 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on JNJ. Royal Bank of Canada lifted their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. Daiwa Capital Markets lowered shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their target price for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. TD Cowen decreased their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Citigroup lifted their price objective on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Finally, The Goldman Sachs Group decreased their target price on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research report on Friday, July 19th. Seven analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $175.00.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $153.28 on Thursday. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The firm’s 50-day moving average is $161.82 and its 200 day moving average is $155.99. The stock has a market cap of $369.04 billion, a price-to-earnings ratio of 22.18, a PEG ratio of 2.71 and a beta of 0.53. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. During the same quarter in the prior year, the company posted $2.66 earnings per share. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. Sell-side analysts anticipate that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.24%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s payout ratio is currently 71.78%.

Insider Buying and Selling

In other news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.